In honor of Prostate Cancer Awareness Month, Oncology Data Advisor Editorial Board Member Ulka Vaishampayan, Professor of Internal Medicine at the University of Michigan Rogel Cancer Center, sat down to discuss the importance of bringing awareness to prostate cancer, up-to-date diagnostic techniques, and updates in therapeutic selection and treatment.  

This interview in honor of Prostate Cancer Awareness Month features Dr. Stephen Freedland, Urologist at Cedars-Sinai Medical Center and Oncology Data Advisor Editorial Board Member, and Dr. Farnoosh Nik-Ahd, Urology Resident at the University of California, San Francisco (UCSF), discussing the risks and incidence of prostate cancer in transgender women. Dr. Nik-Ahd shares the inspiration for her recent first-author study, Prostate Cancer Is Not Just a Man's Concern, the results that she and her team found, and their implications for prostate cancer screening and diagnosis standards for transgender women.  

At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Stephen Freedland, Professor of Urology at Cedars-Sinai Medical Center, sat down with Oncology Data Advisor to discuss his abstract regarding real-world characteristics and treatment by disease volume among patients with metastatic castration-sensitive prostate cancer. Dr. Freedland shares more regarding the complexities of treatment decisions in prostate cancer, barriers to care, and the research that he and his team are conducting to optimize treatment utilization based on disease characteristics.  

At the 48th Annual Oncology Nursing Society (ONS) Congress, Kathy Burns, a Nurse Practitioner at City of Hope Comprehensive Cancer Center, sat down with Oncology Data Advisor® to discuss her presentation regarding the educational need for nurses to stay up-to-date with the best treatment and management options in prostate cancer.   Oncology Da...

At the recent American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, Dr. Lisa Gudenkauf, an Applied Research Scientist at Moffitt Cancer Center, presented her team's research regarding the Functional Assessment of Cancer Therapy—Radionuclide Therapy (FACT-RNT), a novel patient-reported outcomes (PRO) measure for patients with prostate cancer. In this follow-up interview, Dr. Gudenkauf shares more about how the measure was developed, its importance for capturing the patient experience, and its future implementation into both clinical practice and trials.  

In honor of Rare Disease Day on February 28, the Oncology Data Advisor Editorial Board held a live panel discussion that featured updates on rare gastrointestinal cancers from Dr. Thomas Abrams, Assistant Professor of Medicine at Harvard Medical School; perspectives on nursing management of mantle cell lymphoma from Maria Badillo, Research Nurse Manager at MD Anderson Cancer Center; and updates on rare genitourinary cancers from Dr. Ulka Vaishampayan, Professor of Internal Medicine at the University of Michigan Rogel Cancer Center.  

In this interview, Oncology Data Advisor speaks with Dr. Christopher Iannuzzi of Hartford HealthCare about an ongoing clinical trial investigating the personalization of prostate cancer treatment through genomic tumor testing. In addition, Dr. Iannuzzi shares the advantages of delivering stereotactic body radiation therapy and the importance of undergoing prostate cancer screening.  

For this interview in honor of Testicular Cancer Awareness Month, Dr. Sam Kaffenberger, an Assistant Professor of Urology at the University of Michigan Health System, explains the importance of taking a nuanced approach to the management of individual patients with testicular cancer, with the goal of minimizing toxicity and achieving the best possi...

For patients with testicular cancer, planning is necessary to ensure that patients feel prepared regarding the implications of their disease in the years after they finish treatment. In this interview in honor of Testicular Cancer Awareness Month, Dr. Katie Murray, Assistant Professor at the University of Missouri Department of Surgery-Urology, shares advice for members of the cancer care team on how to counsel their patients on planning for life after testicular cancer.  

This interview in honor of Testicular Cancer Awareness Month features Dr. Aditya Bagrodia, an Associate Professor of Urology at the University of California, San Diego. Dr. Bagrodia explains the factors that should be considered when selecting treatment options—including surgery, chemotherapy, radiation, or surveillance—for patients with testicular cancer, the future of recent advances such as cancer detection with microRNA, and the importance of taking a multidisciplinary approach to ensure the best possible outcomes for patients with this disease.